Abstract: Purified nucleic acid encoding a yeast, human, or bovine poly(A) polymerase, where the bovine nucleic acid consists essentially of that nucleic acid sequence shown as nucleotide SEQ. ID. NO.: 1; the resulting recombinant poly(A) polymerase expressed from these nucleic acids, corresponding methods of their production, and methods of use of the poly(A) polymerase.
Type:
Grant
Filed:
November 27, 1991
Date of Patent:
June 11, 1996
Inventors:
Walter Keller, Joachim Lingner, Georges Martin, Elmar Wahle
Abstract: The invention relates to alkaline bacillus lipases, DNA sequences, which code for these lipases, a method for isolating and producing these lipases, as well as to bacillus strains, which have the capability to form these lipases. The alkaline lipases are suitable for use in compositions for cleaning, washing and bleaching purposes.
Type:
Grant
Filed:
October 13, 1992
Date of Patent:
June 27, 1995
Assignee:
Kali-Chemie Aktiengesellschaft
Inventors:
Bernhard Moeller, Roman Vetter, Detlef Wilke, Birgit Foullois
Abstract: A method for preventing or ameliorating HSV infection in a bird or mammal comprises administering a composition comprising an effective amount of an HSV surface glycoprotein and an effective amount of an MDP equivalent, encapsulated in liposomes. The resulting composition is useful for reducing the severity and recurrence of HSV outbreaks.
Type:
Grant
Filed:
October 11, 1991
Date of Patent:
September 22, 1992
Assignees:
Board of Trustees of Leland Chiron Corporation, Stanford Junior University
Inventors:
Rodney Ho, Thomas Merigan, Rae L. Burke, Dino Dina
Abstract: Protein A is selectively isolated from an antibody--Protein A mixture by exposing the mixture to an anion exchange material under conditions sufficient to adsorb both components and then sequentially eluting the antibodies and protein A under conditions of increasing ionic strength. Resulting antibody preparations have less than about 15 ng of Protein A per mg of antibody.
Type:
Grant
Filed:
June 8, 1988
Date of Patent:
January 8, 1991
Assignee:
Miles Inc.
Inventors:
James W. Bloom, Melvin F. Wong, Gautam Mitra
Abstract: A process for producing an active lipase enzyme in vitro, comprising mixing an inactive or partly active lipase enzyme with a chaperone molecule and subjecting the mixture to denaturation followed by renaturation to produce the active lipase enzyme.
Type:
Grant
Filed:
March 3, 1995
Date of Patent:
October 28, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Steen Troels J.o slashed.rgensen, Boerge Krag Diderichsen, Catherine M. Buckley, Audrey Hobson, David J. McConnell
Abstract: Purification of human FSH from post-menopausal urine gonadotropin using immunoaffinity chromatography with elution at high pH and reverse-phase HPLC steps yields a biologically active hormone which is free from detectable traces of luteinizing hormone and other urinary proteins.
Type:
Grant
Filed:
February 7, 1989
Date of Patent:
July 7, 1992
Assignee:
Istituto DiRicerca Cesare Serono SpA
Inventors:
Guiseppe Arpaia, Serenella Serani, Antonino Sirna, Stefano Villa
Abstract: Antimaturation factor (platelet factor 4 or active peptide segments thereof) is employed in the clinical treatment of coagulation disorders as an anticoagulant operating via an autoregulator mechanism for selectively suppressing megakaryocytopoiesis. Exposure of immature megakaryocytes to antimaturation factor reversibly inhibits cell maturation and, accordingly, functions characteristic of the mature cell, including platelet production and expression of genes coding for platelet coagulation factors, are reversibly suppressed.
Abstract: A method for the preparation of a protein in a physiologically active or native form, which method includesproviding a source of protein in a solubilized form,and a cationic exchange medium;contacting the source of protein and cationic exchange medium; andrecovering the protein in a physiologically active form.
Abstract: The present invention relates to a monclonal antibody capable of suppressing the motility of cancer cells, a polypeptide recognizable by said anti-cancer antibody and its fragment peptides which is capable of suppressing the motility of cancer cells.The present invention also relates to a production and a use for preventing the matastasis of cancer thereof.
Abstract: An aqueous solution containing fibrinogen is heated in the presence of at least a sugar, an amino acid and a magnesium salt to thereby inactivate virus(es) possibly contaminating said fibrinogen. According to this process, the inactivation of the contaminating viruses can be achieved while maintaining the activity of the fibrinogen. Thus a highly safe fibrinogen preparation of excellent qualities can be prepared on an industrial scale.
Type:
Grant
Filed:
April 21, 1988
Date of Patent:
May 26, 1992
Assignee:
Green Cross Corporation
Inventors:
Kenmi Miyano, Kenji Tanaka, Hideo Nishimaki, Yoshiro Iga
Abstract: A method for the preparation of proteins in biologically active form including providing a source of protein solubilized from inclusion bodies with a cationic surfactant; providing a weak denaturing agent; and contacting the solubilized protein with the weak denaturant in water in an amount sufficient to allow the protein to remain in a biologically active form.
Abstract: A method kit for purification of m-RNA from a cell are disclosed. Guanidine containing moieties, at high molarity, are use to quickly lyse the cell. They also act to inhibit RNase activity. Without the need for isolation of total RNA, the lysate can then be directly purified from the lysate using oligo dT (or U) by reducing the guanidine concentration via a dilution step.
Type:
Grant
Filed:
May 2, 1994
Date of Patent:
October 17, 1995
Assignee:
Pharmacia P-L Biochemicals Inc.
Inventors:
Christopher D. Wolin, Phillip P. Franciskovich
Abstract: The present invention relates to methods for producing heterologous heme proteins extracellularly comprising transforming a filamentous fungus with a vector comprising a DNA sequence encoding the heterologous heme protein and a DNA sequence encoding a preregion permitting secretion of the expressed heme protein, and culturing the transformed filamentous fungus in a suitable culture medium to produce the heme protein.
Type:
Grant
Filed:
September 30, 1994
Date of Patent:
April 28, 1998
Assignee:
Novo Nordisk A/5
Inventors:
Henrik Dalb.o slashed.ge, Ejner Bech Jensen, Karen Gjesing Welinder
Abstract: A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps. The growth factors may be useful in the promotion of angiogenesis, such as in the promotion of wound healing, bone healing and in the treatment of burns, as well as in promoting the formation, maintenance and repair of tissue, in particular, neural tissue.
Abstract: The recovery of vitamin K-dependent proteins produced by transformed microorganisms can be effected from the cell culture medium utilizing the changes in the protein which occur in the presence of divalent cations. The present process uses divalent cations to alter the binding affinity of the proteins and thereby selectively elute the proteins away from contaminants in the culture medium using standard chromatography.
Abstract: A method for the recovery of proteins in a solubilized form from host cells including providing a source of host cells incorporating a synthesized or expressed protein; providing a source of at least one cationic surfactant; and treating the host cells with at least one cationic surfactant, in an amount sufficient to effect solubilization of the proteins.
Abstract: Biocidal proteins isolated from Mirabilis have been characterized. The proteins show a wide range of antifungal activity and are active against gram-positive bacteria. DNA encoding the proteins has been isolated and incorporated into vectors. Plants transformed with this DNA have been produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
Type:
Grant
Filed:
December 20, 1993
Date of Patent:
January 9, 1996
Assignee:
Imperial Chemical Industries PLC
Inventors:
Miguel De Bolle, Willem F. Broekaert, Bruno P. A. Cammue, Sarah B. Rees, Jozef Vanderleyden
Abstract: The proteins of the invention are specifically recognized by polyclonal anti-AC antibodies raised against purified AC preparations, devoid of adenylate cyclase CaM-activable activity and devoid of affinity for CaM.
Type:
Grant
Filed:
February 20, 1990
Date of Patent:
March 10, 1992
Assignees:
Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
Inventors:
Colette Brezin, Hoang-Oanh Nghiem, Jean Luc Boucaud, Jean M. Alonso
Abstract: This invention provides a family of insecticidally effective proteins and particular members of that family which may be isolated from the venom of the spider Filistata hibernalis, DNA encoding such proteins, insecticidal compositions of these proteins or the DNA encoding them, and methods for controlling invertebrate pests. Recombinant expression vectors and host cells and methods for producing insecticidally effective peptides are also provided.
Type:
Grant
Filed:
July 7, 1993
Date of Patent:
October 10, 1995
Assignees:
FMC Corporation, NPS Pharmaceuticals, Inc.
Inventors:
John R. H. Jackson, Karen J. Krapcho, Janice H. Johnson, Robert M. Kral, Jr.
Abstract: The present invention provides a glycoprotein derived from human cell membrane, which has a molecular weight of 20 to 25 Kd as estimated by SDS polyacrylamide gel electrophoresis, and contains N-glycoside type carbohydrate chain and phosphatidylinositol, and possesses an inhibitory activity to complement-mediated cell membrane damage. The present invention further provides a gene coding for the glycoprotein, and a method for the production of the glycoprotein and the gene therefor.